MOMA Therapeutics has 6 close competitors: AliveCor, UVeye, Cafe Coffee Day.
Sector, valuation and status for each competitor.
A private valuation and a public market cap share one column; each row names its basis and date.
AliveCor
UVeye
Cafe Coffee Day
Cambly
Covariant
Dandelion EnergyPrecision medicine biotech company focused on targeting molecular machines for drug discovery
MOMA Therapeutics competes with 6 companies here: AliveCor, UVeye, Cafe Coffee Day, Cambly, Covariant, Dandelion Energy.
MOMA Therapeutics was last valued at $350M (Apr 2023). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
The last valuation is $350M.
Lead investors for each round are in the funding timeline.
The routes section explains what is realistically available for a company at this stage.
No. MOMA Therapeutics is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
